Europese Unie - IJslands - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - blóðþurrðandi lyf - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf.* - rivaroxabanum inn - filmuhúðuð tafla - 10 mg

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf.* - rivaroxabanum inn - filmuhúðuð tafla - 20 mg

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf.* - rivaroxabanum inn - filmuhúðuð tafla - 15 mg

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

krka d.d. novo mesto* - simvastatinum inn; ezetimibe - tafla - 10 mg/ 40 mg

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

krka d.d. novo mesto* - ezetimibe; simvastatinum inn - tafla - 10 mg/ 20 mg

Europese Unie - IJslands - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - daclatasvir díhýdróklóríð - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - daklinza er ætlað í samsettri meðferð með öðrum lyfjum til meðferðar við langvinna lifrarbólgu c veiru (hcv) sýkingu hjá fullorðnum (sjá kafla 4. 2, 4. 4 og 5. fyrir hcv arfgerð sérstakur starfsemi, sjáðu kafla 4. 4 og 5.

Europese Unie - IJslands - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (sem fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - Æxlishemjandi lyf - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (Úsbekistan)ráðlagt er ætlað fyrir meðferð fullorðinn sjúklinga með polycythaemia vera sem eru ónæmir fyrir eða þola hýdroxýúrea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - quetiapinum fúmarat - filmuhúðuð tafla - 100 mg

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - quetiapinum fúmarat - filmuhúðuð tafla - 200 mg